T-cell recognition of melanoma-associated antigens

Journal of Cellular Physiology

Volumn 182, Issue 3, 2000, Pages 323-331

  Castelli, Chiara ^a   Rivoltini, Licia ^a   Andreola, Giovanna ^a   Carrabba, Matteo ^a   Renkvist, Nicolina ^a   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0033957167     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-4652(200003)182:3<323::aid-jcp2>3.0.co;2-%23     Document Type: Review

References (62)

1. Anichini A, Mazzocchi A, Fossati G, Parmiani G. 1989. T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells: analysis of specificity and mechanisms of interaction. J Immunol 142:3692-3701.
2. Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G. 1996. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156: 208-217.
3. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G. 1999. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190:651-668.
4. Bennink JR, Anderson R, Bacik I, Cox J, Day P, Deng Y, Lapham C, Link H, Russ G, Yewdell JW. 1993. Antigen processing: where tumor-specific T-cell responses begin. J Immunother Emphasis Tumor Immunol 14:202-208.
5. Castelli C, Mazzocchi A, Rini F, Tarsini P, Rivoltini L, Maio M, Gallino G, Belli F, Parmiani G. 1998. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1. Eur J Immunol 28:1143-1154.
6. Castelli C, Tarsini P, Mazzocchi A, Rini F, Rivoltini L, Ravagnani F, Gallino F, Belli F, Parmiani G. 1999. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J Immunol 162:1739-1748.
7. Chan AD, Morton DL. 1998. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 25:611-622.
8. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. 1999. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocyte. J Exp Med 189:767-778.
9. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE. 1994. Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J Exp Med 179: 523-532
10. Cormier JN, Salgaller ML, Prevette, T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3:37-44.
11. Ferrarini M, Imro MA, Sciorati C, Heltai S, Protti MP, Pellicciari C, Rovere P, Manfredi AA, Rugarli C. 1999. Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. Int J Cancer 81:573-579.
12. Ferrone S, Marincola FM. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494.
13. Gervois N, Guilloux Y, Diez E, Jotereau F. 1996. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 183:2403-2407.
14. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T. 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183:1173-1183.
15. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366.
16. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. 1996. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479-2483.
17. Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199-208.
18. Jaffee EM, Pardoll DM. 1996. Murine tumor antigens: is it worth the search? Curr Opin Immunol 8:622-627.
19. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. 1994. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 58:330-339.
20. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968.
21. Kiessling R, Kono K, Petersson M, Wasserman K. 1996. Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol 18:227-242.
22. Labarriere N, Diez E, Pandolfino MC, Viret C, Guilloux Y, Le Guiner S, Fonteneau JF, Dreno B, Jotereau F. 1997. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 158:1238-1245.
23. Lee KH, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA, Marincola FM. 1998. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161:4183-4194.
24. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685.
25. Lethé B, van der Bruggen P, Brasseur F, Boon T. 1997. MAGE-1 expression threshold for the lysis of melanoma cell lines by aspecific cytotoxic T lymphocyte. Melanoma Res 7:S83-S88.
26. Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L. 1996. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 184:647-657.
27. Loftus DJ, Squarcina P, Nielsen MB, Geisler C, Castelli C, Odum N, Appella E, Parmiani G, Rivoltini L. 1998. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res 58:2433-2439.
28. Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, Bordignon C, Sensi M, Parmiani G, Traversari C. 1998. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 188:1005-1006.
29. Madrenas J, Schwartz RH, Germain RN. 1996. Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Proc Natl Acad Sci USA 93:9736-9741.
30. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/ Melan-A antigen. J Clin Invest 98:1633-1641.
31. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP. 1999. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871-876.
32. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented byHLA-A1. Int J Cancer 80:219-230.
33. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. 1996. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 19:266-277.
34. Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, Anichini A. 1994. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer 58:330-339.
35. Mazzocchi A, Storkus WJ, Traversari C, Tarsini P, Maeurer MJ, Rivoltini L, Vegetti C, Belli F, Anichini A, Parmiani G, Castelli C. 1996. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J Immunol 157:3030-3038.
36. McCann J. 1999. Can skin cancers be minimized or prevented in organ transplant patients? J Natl Cancer Inst 91:911-913.
37. Mitchell MS. 1998. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25:623-635.
38. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332.
39. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. 1999. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 20:46-52.
40. Papac RJ. 1998. Spontaneous regression of cancer: possible mechanisms. In Vivo 12:571-578.
41. Parmiani G. 1998. Future perspectives in specific immunotherapy of melanoma. Eur J Cancer 34:S42-S47.
42. Parmiani G, Anichini A, Fossati G. 1990. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 82:361-370.
43. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. 1996. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100-108.
44. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. 1998. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 161:6970-6976.
45. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 154:2257-2265.
46. Rivoltini L, Loftus DJ, Squarcina P, Castelli C, Rini F, Arienti F, Belli F, Marincola FM, Geisler C, Borsatti A, Appella E, Parmiani G. 1998a. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Crit Rev Immunol 18:55-63.
47. Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G. 1998b. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161:1220-1230.
48. Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G. 1999. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 59:301-306.
49. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. 1994. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54:3124-3126.
50. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Liénard D, Cerottini JC, Cerundolo V. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 2:1641-1650.
51. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166.
52. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. 1998a. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327.
53. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE. 1998b. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90:1894-1900.
54. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749-4757.
55. Salvi S, Segalla F, Rao S, Arienti F, Sartori M, Bratina G, Caronni E, Anichini A, Clemente C, Parmiani G, Sensi M. 1995. Overexpression of the T-cell receptor β-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res 55:3374-3379.
56. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527-534.
57. Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. 1999. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 82:669-677.
58. Thomas WD, Hersey P. 1998a. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer 75:384-390.
59. Thomas WD, Hersey P. 1998b. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 161: 2195-2200.
60. Van den Eynde BJ, van der Bruggen P. 1997. T cell defined tumor antigens. Curr Opin Immunol 9:684-693.
61. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. 1999. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284:1351-1354.
62. Whiteside TL, Parmiani G. 1994. Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 39:15-21.